Year 2020 / Volume 27 / Number 1

Abstract PDF HTML

Review

Peripheral acting Mu opioid receptor antagonists in the treatment of the opioid-induced constipation: review

Rev. Soc. Esp. Dolor. 2020; 27(1): 37-49 / DOI: 10.20986/resed.2020.3717/2018

Anna Libran Oriol, Claudia Cruz-Sequeiros, Ana Luque-Blanco, Josep Porta-Sales


ABSTRACT

The opioid induced constipation (OIC) is an emerging clinical problems that worsen the patients’ quality of life requiring opioids for their pain relief. Many drugs have been launched as Peripheral Acting Mu Opioid Receptor Antagonists o PAMORAs (metylnaltrexone, alvimopam and more recently naloxegol), which antagonize the peripheral effects of opioids without affecting the opioids analgesia. Metylnaltrenone and naloxegol have been licensed for the treatment of CIO, meanwhile alvimopam is approved for the recovery of postoperative ileus after major abdominal surgery. All PAMORAs have shown clinical efficacy but is a matter of debate wich should be their role in the manangement of the CIO. The available information about PAMORAs is reviewed and informed strategy on the use of these drugs is proposed.



RESUMEN

El estreñimiento inducido por opioides (EIO) constituye un problema clínico emergente que empeora la calidad de vida de los pacientes que requieren el uso de opioides para el manejo del dolor. Diferentes fármacos se han comercializado como antagonistas de los receptores opioides Mu periféricos, conocidos con el nombre de Peripheral Acting Mu Opioid Receptor Antagonists o PAMORA (metilnaltrexona, alvimopam y más recientemente naloxegol), que permiten la antagonización de los efectos periféricos de los opioides sin interferir en su efecto analgésico. Tanto metilnaltrexona como naloxegol han sido aprobados para el tratamiento del EIO, mientras que alvimopan está aprobado para la recuperación gastrointestinal después de resección intestinal con anastomosis primaria. Todos ellos han mostrado su eficacia clínica, pero es debatido el papel que han de tener en la estrategia global del manejo del EIO. Se revisa la información disponible sobre los PAMORA y se propone estrategia de uso clínico.





Complete Article

Nuevo comentario

Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comentarios

01/11/2023 21:45:05
Prosperadlo. En 2008, durante una prótesis de cadera en el Royal Orthopedic hospital de Londres, se produjo una infección y, como resultado, una alta amputación de la pierna. Durante 15 años he estado plagado de fuertes dolores fantasmas. Debido a la ingesta prolongada de opioides (morfina), desarrollé bloqueos estables similares a una obstrucción. Miró su sitio web y decidió escribirle una pregunta para obtener Consejo, ayuda. Estaré agradecido por la respuesta. Saludos Stepan 76 años
Mi correo electrónico: boxsito072@gmail.com
República de Chipre, ciudad de Limassol

Bibliografía

1. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31(1):58-69.
DOI: 10.1016/j.jpainsymman.2005.06.007
2. Moens K, Higginson IJ, Harding R; EURO IMPACT. Are There Differences in the Prevalence of Palliative Care-Related Problems in People Living With Advanced Cancer and Eight Non-Cancer Conditions ? A Systematic Review. J Pain Symptom Manage. 2014;48(4):660-77.
DOI: 10.1016/j.jpainsymman.2013.11.009
3. Clark K, Lam LT, Talley NJ, Philips JL, Currow DC. Identifying Factors That Predict Worse Constipation Symptoms in Palliative Care Patients: A Secondary Analysis. J Palliat Med. 2017;20(5):528-32.
DOI: 10.1089/jpm.2016.0331
4. Erichsén E, Milberg A, Jaarsma T, Friedrichsen MJ. Constipation in Specialized Palliative Care: Prevalence, Definition, and Patient-Perceived Symptom Distress. J Palliat Med. 2015;18(7):585-92.
DOI: 10.1089/jpm.2014.0414
5. Shih DQ, Kwan LY. All Roads Lead to Rome: Update on Rome III Criteria and New Treatment Options. Gastroenterol Rep. 2007;1(2):56-65.
6. Librach SL, Bouvette M, De Angelis C, Farley J, Oneschuk D, Pereira JL, et al. Consensus recommendations for the management of constipation in patients with advanced, progressive illness. J Pain Symptom Manage. 2010;40(5):761-73.
DOI: 10.1016/j.jpainsymman.2010.03.026
7. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines : a longitudinal follow-up study of symptom prevalence , severity and etiology. Pain. 2001;93(3):247-57.
DOI: 10.1016/S0304-3959(01)00324-4
8. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63.
DOI: 10.5056/jnm16214
9. Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr Gastroenterol Rep. 2017;19(4):15.
DOI: 10.1007/s11894-017-0554-0
10. Brock C, Olesen SS, Olesen AE, Frøkjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72(14):1847-65.
DOI: 10.2165/11634970-000000000-00000
11. Floettmann E, Bui K, Sostek M, Payza K, Eldon M. Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation. J Pharmacol Exp Ther. 2017;361(2):280-91.
DOI: 10.1124/jpet.116.239061
12. Oosten AW, Oldenmenger WH, Mathijssen RHJ, Rijt CCD Van Der. A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures. J Pain. 2015;16(10):935-46.
DOI: 10.1016/j.jpain.2015.05.006
13. Clark K, Lam LT, Agar M, Chye R, Currow DC. The impact of opioids, anticholinergic medications and disease progression on the prescription of laxatives in hospitalized palliative care patients: a retrospective analysis. Palliat Med. 2010;24(4):410-8.
DOI: 10.1177/0269216310363649
14. Miles C, Fellowes D, Ml G, Ssm W, Miles C, Fellowes D, et al. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003448. DOI: 10.1002/14651858.CD003448.pub2.
15. Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24(12):3503-12.
DOI: 10.1185/03007990802584454
16. Mercadante S, Ferrera P AC. High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer. 2011;19(9):1471-2.
DOI: 10.1007/s00520-011-1205-x
17. Diego L, Atayee R, Helmons P, Hsiao G von GC. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011;20(8):1047-56.
DOI: 10.1517/13543784.2011.592830
18. Kunøe N, Opheim A, Solli KK, Gaulen Z, Sharma-Haase K, Latif Z-E-H, et al. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). BMC Pharmacol Toxicol. 2016;17(1):18.
DOI: 10.1186/s40360-016-0061-1
19. Chen KY, Chen L, Mao J. Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014;120(5):1262-74.
DOI: 10.1097/ALN.0000000000000170
20. Weinrib AZ, Burns LC, Mu A, Azam MA, Ladak SSJ, McRae K, et al. A case report on the treatment of complex chronic pain and opioid dependence by a multidisciplinary transitional pain service using the ACT matrix and buprenorphine/naloxone. J Pain Res. 2017;10:747-55.
DOI: 10.2147/JPR.S124566
21. Webster LR, Camilleri M, Finn A. Opioid-induced constipation : rationale for the role of norbuprenorphine in buprenorphine- treated individuals. Subst Abuse Rehabil. 2016;7:81-6.
DOI: 10.2147/SAR.S100998
22. Yuan CS, Foss JF, O’Connor M, Toledano A, Roizen MF MJ. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther. 1996;59(4):467-75.
DOI: 10.1016/S0009-9236(96)90117-4
23. Yuan CS, Doshan H, Charney MR, O’connor M, Karrison T, Maleckar SA, et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005;45(5):538-46.
DOI: 10.1177/0091270004273491
24. Chandrasekaran A, Tong Z, Li H, Erve JCL, DeMaio W, Goljer I, et al. Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans. Drug Metab Dispos. 2010;38(4):606-16.
DOI: 10.1124/dmd.109.031179
25. Rotshteyn Y, Boyd TA, Yuan CS. Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration. Expert Opin Drug Metab Toxicol. 2011;7(2):227-35.
DOI: 10.1517/17425255.2011.549824
26. Zacnya JP, Wroblewskib K, Coalson DW. Methylnaltrexone: Its Pharmacological Effects Alone and Effects on Morphine in Healthy Volunteers. Psychopharmacol (Berl). 2015;232(1):63-73.
DOI: 10.1007/s00213-014-3637-8
27. Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, et al. Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study. J Pain Symptom Manage. 2008;35(5):458-68.
DOI: 10.1016/j.jpainsymman.2007.12.005
28. Mori M, Ji Y, Kumar S, Ashikaga T, Ades S. Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study. Int J Clin Oncol. 2017;22(2):397-404.
DOI: 10.1007/s10147-016-1041-6
29. Anissian L, Schwartz HW, Vincent K, Vincent HK, Carpenito J, Stambler N, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: Phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012;7(2):67-72.
DOI: 10.1002/jhm.943
30. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness. N Engl J Med. 2008;358(22):2332-43.
DOI: 10.1056/NEJMoa0707377
31. Michna E, Blonsky ER, Schulman S, Tzanis E, Manley A, Zhang H, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: A randomized controlled study. J Pain. 2011;12(5):554-62.
DOI: 10.1016/j.jpain.2010.11.008
32. Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39-46.
33. Yu CS, Chun HK, Stambler N, Carpenito J, Schulman S, Tzanis E, et al. Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: Results of two randomized, placebo-controlled phase 3 trials. Dis Colon Rectum. 2011;54(4):570-8. DOI: 10.1007/DCR.0b013e3182092bde.
DOI: 10.1007/DCR.0b013e3182092bde
34. Mehta N, O’Connell K, Giambrone GP, Baqai A, Diwan S. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review. Postgrad Med. 2016;128(3):282-9.
DOI: 10.1080/00325481.2016.1149017
35. Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension. J Palliat Med. 2015;18(7):593-600.
DOI: 10.1089/jpm.2014.0362
36. Greenwood-Van Meerveld B, Gardner CJ, Little PJ, Hicks GA, Dehaven-Hudkins DL. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil. 2004;16(Suppl. 2):46-53.
DOI: 10.1111/j.1743-3150.2004.00555.x
37. Liu SS, Hodgson PS, Carpenter R, Fricke JR Jr. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther. 2001;69(1):66-71.
DOI: 10.1067/mcp.2001.112680
38. Kraft M, Maclaren R, Du W, Owens G. Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection. P T. 2010;35(1):44-9.
39. JF Foss, DM Fisher VS, Schmith VD. Pharmacokinetics of Alvimopan and Its Metabolite in Healthy Volunteers and Patients in Postoperative Ileus Trials. Clin Pharmacol Ther. 2008;83(5):770-6.
DOI: 10.1038/sj.clpt.6100292
40. Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M, et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001;345(13):935-40.
DOI: 10.1056/NEJMoa010564
41. Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, et al. Alvimopan, a Novel, Peripherally Acting _ Opioid Antagonist Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Major Abdominal Surgery and Postoperative Ileus. Ann Surg. 2004;240(4):728-35. DOI: 10.1097/01.sla.0000141158.27977.66.
DOI: 10.1097/01.sla.0000141158.27977.66
42. Delaney CP, Weese JL, Hyman NH, Bauer J, Techner L, Gabriel K, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005;48(6):1114-25.
DOI: 10.1007/s10350-005-0035-7
43. Viscusi ER, Goldstein S, Witkowski T, Andonakakis a, Jan R, Gabriel K, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc. 2006;20(3):64-70.
DOI: 10.1007/s00464-005-0104-y
44. Büchler MW, Seiler CM, Monson JR, Flamant Y, Thompson-Fawcett MW, Byrne MM, et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. 2008;28(3):312-25.
DOI: 10.1111/j.1365-2036.2008.03696.x
45. Wolff BG, Weese JL, Ludwig KA, Delaney CP, Stamos MJ, Michelassi F, et al. Postoperative Ileus-Related Morbidity Profile in Patients Treated with Alvimopan after Bowel Resection. J Am Coll Surg. 2007;204(4):609-16.
DOI: 10.1016/j.jamcollsurg.2007.01.041
46. Herzog TJ, Coleman RL, Guerrieri JP, Gabriel K, Du W, Techner L, et al. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol. 2006;195(2):445-53.
DOI: 10.1016/j.ajog.2006.01.039
47. Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cance. Pain. 2008;137(2):428-40.
DOI: 10.1016/j.pain.2007.11.008
48. Siemens W, Gaertner J, Becker G. Advances in pharmacotherapy for opioid-induced constipation - a systematic review. Expert Opin Pharmacother. 2015;16(4):515-32.
DOI: 10.1517/14656566.2015.995625
49. Irving G, Pénzes J, Ramjattan B, Cousins M, Rauck R, Spierings EL, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12(2):175-84.
DOI: 10.1016/j.jpain.2010.06.013
50. Bui K, She F, Hutchison M, Brunnström Å, Sostek M. Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects. Int J Clin Pharmacol Ther. 2015;53(10):838-46.
DOI: 10.5414/CP202276
51. Floettmann E, Bui K, Sostek M, Payza K, Eldon M. Pharmacologic Profile of Naloxegol, a Peripherally Acting μ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation. J Pharmacol Exp Ther. 2017;361(2):280-91.
DOI: 10.1124/jpet.116.239061
52. Bui K, Birmingham B, Diva U, Berger B. An Open-Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects. Clin Pharmacol Drug Dev. 2017;6(4):420-27.
DOI: 10.1002/cpdd.335
53. Bui K, Zhou D, Sostek M, She F, Al-Huniti N. Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol. J Clin Pharmacol. 2016;56(8):1019-27.
DOI: 10.1002/jcph.693
54. Bui K, She F, Zhou D, Butler K, Al-Huniti N, Sostek M. The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. J Clin Pharmacol. 2016;56(4):497-505.
DOI: 10.1002/jcph.613
55. Eldon MA, Kugler AR, Medve RA, Bui K, Butler K, Sostek M. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study. Clin Pharmacol Drug Dev. 2015;4(6):434-41.
DOI: 10.1002/cpdd.206
56. Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014;54(12):1375-82.
DOI: 10.1002/jcph.349
57. Bui K, She F, Sostek M. The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014;54(12):1368-74.
DOI: 10.1002/jcph.348
58. Bui K, Zhou D, Xu H, Floettmann E, Al-Huniti N. Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist. Clin Pharmacokinet. 2016;56(6):573-82.
DOI: 10.1007/s40262-016-0479-z
59. Webster LR, Yamada T, Ferreira JCA. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Chronic Non-Cancer Pain. Pain Med. 2017;18(12):2350-60.
DOI: 10.1093/pm/pnw325
60. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387-96.
DOI: 10.1056/NEJMoa1310246
61. Von Roenn JH, Tack J, Barker PN et al. Challenges in patient recruitment during KODIAC-06, a randomized, placebo-controlled, double-blind, multicenter, phase 3 trial of naloxegol in patients with neoplasia and opioid-induced constipation (OIC). Poster session presented at: MASCC/ISOO International Symposium on Supportive Care in Cancer Jun 27–29, 2013; Berlin, Germany. 2013. p. Poster no. 67568.
62. Webster L, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical trial: The long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40(7):771-9.
DOI: 10.1111/apt.12899
63. Esmadi M, Ahmad D, Hewlett A. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis. J Gastrointestin Liver Dis. 2019;28(1):41-6. DOI: 10.15403/jgld.2014.1121.281.any.
DOI: 10.15403/jgld.2014.1121.281.any
64. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63.
DOI: 10.5056/jnm16214
65. Mcquade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-Induced Constipation and Diarrhea : Pathophysiology , Current and Emerging Treatments. Front Pharmacol. 2016;7:414.
DOI: 10.3389/fphar.2016.00414
66. Holder RM, Rhee D. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain. Pharmacotherapy. 2016;36(3):287-99.
DOI: 10.1002/phar.1711
67. Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, et al. Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation. Pain Med. 2015;16(12):2324-37.
DOI: 10.1111/pme.12937
68. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12(4):371-83.
DOI: 10.3111/13696990903430481
69. Ducrotté P, Caussé C. The Bowel Function Index: a new validated scale for assessing opioid-induced constipation. Curr Med Res Opin. 2012;28(3):457-66.
DOI: 10.1185/03007995.2012.657301
70. Friedman JD, Dello Buono F. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother. 2001;35(1):85-91.
DOI: 10.1345/aph.10121
71. Kumar N, Garg N, Bailey A. Opiate receptor antagonists for treatment of severe pruritus associated with advanced cholestatic liver disease. J Palliat Med. 2013;16(2):122-3.
DOI: 10.1089/jpm.2012.0452
72. Hohl CM, Wong JK, Harlos MS. Methylnaltrexone to palliate pruritus in terminal hepatic disease. J Palliat Care. 2015;31(2):124-6.
DOI: 10.1177/082585971503100209
73. Zand F, Amini A, Asadi S, Farbood A. The effect of methylnaltrexone on the side effects of intrathecal morphine after orthopedic surgery under spinal anesthesia. Pain Pract. 2015;15(4):348-54.
DOI: 10.1111/papr.12185
74. Paech M, Sng B, Ng L, Nathan E, Sia A, Carvalho B. Methylnaltrexone to prevent intrathecal morphine-induced pruritus after Caesarean delivery: A multicentre, randomized clinical trial. Br J Anaesth. 2015;114(3):469-76.
DOI: 10.1093/bja/aeu410
75. Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P. Laxatives for the management of constipation in people receiving palliative care. The Cochrane database of systematic reviews. 2015;(5):CD003448.
DOI: 10.1002/14651858.CD003448.pub4

Tablas y Figuras

Table I

Table II

Table III

Table IV

Figure 1

Artículos relacionados

Pain trajectories and neuropathic pain symptoms following lung cancer surgery: a prospective cohort study

Rev. Soc. Esp. Dolor. 2023; 30(4): 270-283 / DOI: 10.1002/ejp.2265

Abdominopelvic neuropathic pain secondary to involvement of the anterior cutaneous, iliohypogastric, and ilioinguinal nerves: case report and review of the literature

Rev. Soc. Esp. Dolor. 2023; 30(4): 265-269 / DOI: 10.20986/resed.2024.4054/2023

Fibromyalgia, mitochondrial dysfunction, oxidative stress and inflammation: ozone as a multitarget treatment. Case report and review of literature

Rev. Soc. Esp. Dolor. 2023; 30(4): 258-264 / DOI: 10.20986/resed.2023.3987/2022

Exosomes as a potential therapeutic strategy for low back pain: literature review

Rev. Soc. Esp. Dolor. 2023; 30(4): 243-249 / DOI: 10.20986/resed.2023.4075/2023

Care needs of intrathecal infusion therapy in patients with cancer pain

Rev. Soc. Esp. Dolor. 2023; 30(4): 227-242 / DOI: 10.20986/resed.2024.4099/2023

Continuous electrical stimulation for the treatment of trigeminal neuralgia. A systematic review

Rev. Soc. Esp. Dolor. 2023; 30(4): 217-226 / DOI: 10.20986/resed.2023.4043/2022

Problems and adverse reactions related to dipyrone in Colombia

Rev. Soc. Esp. Dolor. 2023; 30(4): 210-216 / DOI: 10.20986/resed.2023.4025/2022

Editorial by the President of the Spanish Pain Society

Rev. Soc. Esp. Dolor. 2024; 31(13): 1-1

Editorial by the President of the Spanish Pain Society

Rev. Soc. Esp. Dolor. 2023; 30(14): 1-1

Abstracts

Rev. Soc. Esp. Dolor. 2023; 30(13): 3-169

Editorial by the President of the Spanish Pain Society

Rev. Soc. Esp. Dolor. 2023; 30(13): 1-1

Virtual reality increases pressure pain threshold and lowers anxiety in children compared with control and non-immersive control— randomized, crossover trial

Rev. Soc. Esp. Dolor. 2023; 30(3): 196-206

Persistent headache after craniotomy for meningioma: charting of the afferent pathways for nociception: a discussion

Rev. Soc. Esp. Dolor. 2023; 30(3): 191-195 / DOI: 10.20986/resed.2023.4069/2023

A case of neuralgic amyotrophy after vaccination against COVID-19

Rev. Soc. Esp. Dolor. 2023; 30(3): 187-190 / DOI: 10.20986/resed.2023.4021/2022

Ultrasound-guided ankle nerve block as adjuvant therapy in chronic pain after occupational injury.

Rev. Soc. Esp. Dolor. 2023; 30(3): 178-186 / DOI: 10.20986/resed.2023.4035/2022

Effectiveness of adding posterior capsule stretching after an exercise program in patients with subacromial impingement syndrome: a randomized clinical study

Rev. Soc. Esp. Dolor. 2023; 30(3): 168-177 / DOI: 10.20986/resed.2023.3927/2021

Impact on quality of life, depression and analgesic use, are associated with suffering in fibromyalgia patients. A cross-sectional study

Rev. Soc. Esp. Dolor. 2023; 30(3): 159-167 / DOI: 10.20986/resed.2023.4061/2023

A road trip to chemotherapy-induced neuropathic pain

Rev. Soc. Esp. Dolor. 2023; 30(3): 155-156 / DOI: 10.20986/resed.2023.4110/2023

Pain paths among post-COVID-19 condition subjects: a prospective cross-sectional study with in-person evaluation

Rev. Soc. Esp. Dolor. 2023; 30(2): 131-145 / DOI: 10.1002/ejp.2094

Pharmacogenetics in analgesic response: towards a sex-differences personalized medicine

Rev. Soc. Esp. Dolor. 2023; 30(2): 115-124 / DOI: 10.20986/resed.2023.4042/2022

Superior hypogastric plexus block for the management of non-oncological chronic pelvic pain: effectiveness and safety

Rev. Soc. Esp. Dolor. 2023; 30(2): 109-114 / DOI: 10.20986/resed.2023.4038/2022

Effect of therapeutic exercise in persons with sacroiliac joint dysfunction: a systematic review and meta-analysis

Rev. Soc. Esp. Dolor. 2023; 30(2): 95-108 / DOI: 10.20986/resed.2023.4034/2022

Knowledge, attitudes, and beliefs towards the disease in women with fibromyalgia. A qualitative study based on a focus group

Rev. Soc. Esp. Dolor. 2023; 30(2): 79-94 / DOI: 10.20986/resed.2023.4022/2022

Observational, prospective and multicenter study on the use of transmucosal fentanyl citrate in regular clinical practice for the control of breakthrough pain crises in cancer patients

Rev. Soc. Esp. Dolor. 2023; 30(2): 72-78 / DOI: 10.20986/resed.2023.4028/2022

Letter of reply to the article “Updates on the therapeutic approach in complex regional pain syndrome”

Rev. Soc. Esp. Dolor. 2023; 30(1): 63-64 / DOI: 10.20986/resed.2023.4049/2022

Not just low back pain: atypical manifestation of aortic aneurysm

Rev. Soc. Esp. Dolor. 2023; 30(1): 60-62 / DOI: 10.20986/resed.2022.3983/2022

Effects of transcranial direct current stimulation in pain and opioid consumption after spine surgery

Rev. Soc. Esp. Dolor. 2023; 30(1): 49-59 / DOI: 10.1002/ejp.1985

Pulsed radiofrequency of the supraescapular nerve in the treatment of painful shoulder

Rev. Soc. Esp. Dolor. 2023; 30(1): 36-48 / DOI: 10.20986/resed.2023.4046/2022

Effectiveness of cluneal nerve block for the treatment of chronic low back pain

Rev. Soc. Esp. Dolor. 2023; 30(1): 30-35 / DOI: 10.20986/resed.2023.4023/2022

Review of the remission and management of a cancer related pain population to a pain unit. What can we improve?

Rev. Soc. Esp. Dolor. 2023; 30(1): 7-14 / DOI: 10.20986/resed.2023.4010/2022

Can suicidal behaviour in chronic pain patients be prevented?

Rev. Soc. Esp. Dolor. 2023; 30(1): 5-6 / DOI: 10.20986/resed.2023.4080/2023

Noninvasive vagus nerve stimulation in trigeminal pain and trigemino-vagal system

Rev. Soc. Esp. Dolor. 2023; 30(1): 3-4 / DOI: 10.20986/resed.2023.4057/2023

Effectiveness of electroacupuncture and moxibustion in the treatment of postoperative anterior cruciate ligament graft pain with meniscal remodeling. Case study UNEVT 2022

Rev. Soc. Esp. Dolor. 2022; 29(3): 192-195 / DOI: 10.20986/resed.2022.4009/2022

Treatment of painful scars with 5 % lidocaine patch: clinical cases report

Rev. Soc. Esp. Dolor. 2022; 29(3): 187-191 / DOI: 10.20986/resed.2022.3997/2022

Long-term effectiveness of epidural steroid injections after new episodes of low back pain in older adults

Rev. Soc. Esp. Dolor. 2022; 29(3): 175-186 / DOI: 10.1002/ejp.1975

Usefulness of percutaneous basivertebral nerve thermorizotomy for the treatment of chronic low back pain. Literature review

Rev. Soc. Esp. Dolor. 2022; 29(3): 169-174 / DOI: 10.20986/resed.2022.4044/2022

Efficacy of physiotherapy on the anxiety and depression in patients with chronic pain: a systematic review

Rev. Soc. Esp. Dolor. 2022; 29(3): 157-168 / DOI: 10.20986/resed.2022.3994/2022

Psychological intervention program to promoted active coping in patients with chronic back pain

Rev. Soc. Esp. Dolor. 2022; 29(3): 149-156 / DOI: 10.20986/resed.2022.3993/2022

Single eco-guided intra-articular injection of hyaluronic acid in symptomatic coxarthrosis: retrospective study of the efficacy of two presentations

Rev. Soc. Esp. Dolor. 2022; 29(3): 140-148 / DOI: 10.20986/resed.2022.4014/2022

Can we modify the evolution of neuropathic pain through the skin?

Rev. Soc. Esp. Dolor. 2022; 29(3): 129-131 / DOI: 10.20986/resed.2022.4052/2022

Pain as a conditioned response

Rev. Soc. Esp. Dolor. 2022; 29(3): 127-128 / DOI: 10.20986/resed.2022.4051/2022

Another step forward in pain education: European Journal of Pain articles now in spanish language

Rev. Soc. Esp. Dolor. 2022; 29(3): 125-126 / DOI: 10.20986/resed.2022.4050/2022

Pain and rehabilitation in Parsonage-Tuner syndrome due to SARS-CoV-2: a case report

Rev. Soc. Esp. Dolor. 2022; 29(2): 119-123 / DOI: 10.20986/resed.2022.3940/2021

Peripheral facial palsy following glossopharyngeal block: a case report

Rev. Soc. Esp. Dolor. 2022; 29(2): 114-118 / DOI: 10.20986/resed.2022.3963/2021

The biopsychosocial nature of chronic pelvic floor pain: a narrative review

Rev. Soc. Esp. Dolor. 2022; 29(2): 97-113 / DOI: 10.20986/resed.2022.3981/2022

Myofascial pain syndrome in the female pelvic floor musculature. Narrative review of the literature

Rev. Soc. Esp. Dolor. 2022; 29(2): 88-96 / DOI: 10.20986/resed.2022.3970/2022

Effects of hydrotherapy on pain in osteoarthritis and fibromyalgia: a narrative review

Rev. Soc. Esp. Dolor. 2022; 29(2): 78-87 / DOI: 10.20986/resed.2022.3955/2021

Impact of the use of patient-controlled epidural analgesia on pain reduction during labor in a hospital in southwestern colombia

Rev. Soc. Esp. Dolor. 2022; 29(2): 71-77 / DOI: 10.20986/resed.2022.3959/2021

Cross-sectional study on factors related to chronic pain and its care, according to sex

Rev. Soc. Esp. Dolor. 2022; 29(2): 61-70 / DOI: 10.20986/resed.2022.3968/2022

Attitudes and current knowledge of the spanish pain treatment specialist regarding medical cannabis

Rev. Soc. Esp. Dolor. 2022; 29(13): 52-57 / DOI: 10.20986/resed.2022.4032/2022

Practical aspects of product selection and titration with medical cannabis for chronic pain management

Rev. Soc. Esp. Dolor. 2022; 29(13): 43-51 / DOI: 10.20986/resed.2022.4031/2022

Medical cannabis treatment in patients with visceral chronic pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 32-42 / DOI: 10.20986/resed.2022.4030/2022

Is medical cannabis useful for the treatment of fibromyalgia?

Rev. Soc. Esp. Dolor. 2022; 29(13): 27-31 / DOI: 10.20986/resed.2022.4029/2022

Cannabinoids in neuropathic pain: lights and shadows

Rev. Soc. Esp. Dolor. 2022; 29(13): 20-26 / DOI: 10.20986/resed.2022.4027/2022

Medical cannabis and cancer: benefits for cancer pain and other related symptoms

Rev. Soc. Esp. Dolor. 2022; 29(13): 14-19 / DOI: 10.20986/resed.2022.4026/2022

Current evidence of medical cannabis treatment in patients with chronic pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 10-13 / DOI: 10.20986/resed.2022.4024/2022

Some preclinical results of cannabinoids and pain

Rev. Soc. Esp. Dolor. 2022; 29(13): 3-9 / DOI: 10.20986/resed.2022.4033/2022

Lights and shadows of treating pain with medical cannabis

Rev. Soc. Esp. Dolor. 2022; 29(13): 1-2 / DOI: 10.20986/resed.2022.4036/2022

Bone pain management with opioid medication in a patient with Camurati-Engelmann disease: a case report

Rev. Soc. Esp. Dolor. 2022; 29(1): 51-55 / DOI: 10.20986/resed.2021.3930/2021

Complex regional pain syndrome, rehabilitation, pharmacotherapy, psychology.

Rev. Soc. Esp. Dolor. 2022; 29(1): 34-50 / DOI: 10.20986/resed.2022.3978/2022

Use of 8 % capsaicin patches for the treatment of lumbar neuropathic pain

Rev. Soc. Esp. Dolor. 2022; 29(1): 28-33 / DOI: 10.20986/resed.2022.3995/2022

Ultrasound guided interlaminar epidural steroid injection: the cumulative sum method (CUSUM) for performance evaluation

Rev. Soc. Esp. Dolor. 2022; 29(1): 21-27 / DOI: 10.20986/resed.2022.3988/2022

Evaluation of the analgesic efficacy of lumbar facet block as a function of the imaging technique used: ultrasound versus fluoroscopy

Rev. Soc. Esp. Dolor. 2022; 29(1): 15-20 / DOI: 10.20986/resed.2022.3969/2021

OFA in major surgery. Experience at a secondary level hospital

Rev. Soc. Esp. Dolor. 2022; 29(1): 8-14 / DOI: 10.20986/resed.2022.3991/2022

Spontaneous pain is very "sympathetic"

Rev. Soc. Esp. Dolor. 2022; 29(1): 4-5 / DOI: 10.20986/resed.2022.3999/2022

Complex regional pain syndrome: the challenges and opportunities of an evolving disease

Rev. Soc. Esp. Dolor. 2022; 29(1): 1-3 / DOI: 10.20986/resed.2022.3998/2022

Peroneal neuropathy caused by an extraneural ganglion: literary review and treatment proposal. A non-positive case

Rev. Soc. Esp. Dolor. 2021; 28(6): 354-357 / DOI: 10.20986/resed.2022.3919/2021

Retrolaminar ultrasound guided block as analgesic treatment for post herpetic neuralgia: case report

Rev. Soc. Esp. Dolor. 2021; 28(6): 350-353 / DOI: 10.20986/resed.2022.3920/2021

Recommendations for the safe prescription of opioids in patients with a history or risk of abuse

Rev. Soc. Esp. Dolor. 2021; 28(6): 343-349 / DOI: 10.20986/resed.2022.3935/2021

Use of botulinum toxin for pain after amputation

Rev. Soc. Esp. Dolor. 2021; 28(6): 332-342 / DOI: 10.20986/resed.2022.3943/2021

Lumbar epidural steroids injections reduce catastrophism on the lumbosacral radicular syndrome

Rev. Soc. Esp. Dolor. 2021; 28(6): 325-331 / DOI: 10.20986/resed.2022.3947/2021

End-of-life transfusions in patients with an oncological diagnosis

Rev. Soc. Esp. Dolor. 2021; 28(6): 319-324 / DOI: 10.20986/resed.2022.3956/2021

Preliminary study on the evaluation of mechanical pressure pain and central pain modulation mechanisms by algometry in an anesthesia unit

Rev. Soc. Esp. Dolor. 2021; 28(6): 311-318 / DOI: 10.20986/resed.2022.3885/2021

New opioids with different intracellular mechanism of action; is a new therapeutic window opening up?

Rev. Soc. Esp. Dolor. 2021; 28(5): 292-297 / DOI: 10.20986/resed.2021.3891/2021

Thalalgic triad. A new clinical entity from a case series

Rev. Soc. Esp. Dolor. 2021; 28(5): 276-281 / DOI: 10.20986/resed.2021.3941/2021

Efficacy and complications of analgesic techniques for the treatment of moderate to severe postoperative acute pain

Rev. Soc. Esp. Dolor. 2021; 28(5): 264-265 / DOI: 10.20986/resed.2021.3942/2021

Descriptive study on the profile of patients sent to the Chronic Pain Treatment Unit of the University Hospital of Gran Canaria Dr. Negrín (UTDC-HUGCDN) as a basis for the reorganization of this

Rev. Soc. Esp. Dolor. 2021; 28(5): 254-263 / DOI: 10.20986/resed.2021.3939/2021

Myalgic encephalitis or chronic fatigue syndrome, implications in its approach in pain units in the post-COVID era

Rev. Soc. Esp. Dolor. 2021; 28(5): 250-251 / DOI: 10.20986/resed.2021.3960/2021

Pain, emotions and locus coeruleus

Rev. Soc. Esp. Dolor. 2021; 28(5): 247-249 / DOI: 10.20986/resed.2021.3965/2021

Treatment by ultrasound-guided neurolysis with 6 % aqueous phenol of the pain component for post-amputation neuromas: report of a clinical case

Rev. Soc. Esp. Dolor. 2021; 28(4): 239-241 / DOI: 10.20986/resed.2021.3928/2021

The unsolved problem of postoperative pain: critical analysis and prospects for improvement

Rev. Soc. Esp. Dolor. 2021; 28(4): 232-238 / DOI: 10.20986/resed.2021.3917/2021

Dorsal root ganlion pulsed radiofrequency for lumbosacral radicular pain: a narrative review

Rev. Soc. Esp. Dolor. 2021; 28(4): 219-231 / DOI: 10.20986/resed.2021.3882/2021

Clinical recommendations for rehabilitation of people with fibromyalgia. A narrative review

Rev. Soc. Esp. Dolor. 2021; 28(4): 194-210 / DOI: 10.20986/resed.2021.3932/2021

Psychological factors associated with the adherence to analgesic treatment in patients with chronic pain: systematic review of the literature

Rev. Soc. Esp. Dolor. 2021; 28(4): 181-193 / DOI: 10.20986/resed.2021.3922/2021

Comment to the article “radiofrequency intraosseous ablation of the vertebral basicervical nerve. Solution in refractory discogenic pain?”

Rev. Soc. Esp. Dolor. 2021; 28(2): 172-173 / DOI: 10.20986/resed.2021.3929/2021

Persistent hiccups after epidural injection of betamethasone: a case report

Rev. Soc. Esp. Dolor. 2021; 28(2): 169-171 / DOI: 10.20986/resed.2021.3914/2021

Genicular nerve radiofrequency in osteoarthritis-related chronic knee pain

Rev. Soc. Esp. Dolor. 2021; 28(3): 154-168 / DOI: 10.20986/resed.2021.3900/2021

Observational and prospective study on the effectiveness and safety of the dorsal root ganglion stimulation in patients with refractory neuropathic pain

Rev. Soc. Esp. Dolor. 2021; 28(2): 148-156 / DOI: 10.20986/resed.2021.3879/2020

Prescribing habits for neuropathic pain management in Spain: results of the survey of the neuropathic pain working group of the Spanish Pain Society

Rev. Soc. Esp. Dolor. 2021; 28(3): 137-147 / DOI: 10.20986/resed.2021.3911/2021

Epidemiological profile of pain secondary to moderate diabetic peripheral neuropathy

Rev. Soc. Esp. Dolor. 2021; 28(2): 129-136 / DOI: 10.20986/resed.2021.3826/2020

Results of an interdisciplinary psychoeducational intervention with EMDR in patients with fibromyalgia: a private center experience

Rev. Soc. Esp. Dolor. 2021; 28(2): 119-128 / DOI: 10.20986/resed.2021.3897/2021

Transcutaneous electrical nerve stimulation (TENS) as effective pain and fatigue management in women with fibromyalgia

Rev. Soc. Esp. Dolor. 2021; 28(2): 117-118 / DOI: 10.20986/resed.2021.3931/2021

Does it decrease the efficacy or safety of COVID-19 vaccines in patients with chronic pain?

Rev. Soc. Esp. Dolor. 2021; 28(2): 115-116 / DOI: 10.20986/resed.2021.3933/2021

Neuropathic pain: a constant challenge

Rev. Soc. Esp. Dolor. 2021; 28(2): 111-114 / DOI: 10.20986/resed.2021.3938/2021

Botulinum toxin for the treatment of myofascial pain syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 100-110 / DOI: 10.20986/resed.2021.3902/2021

Postoperative ketamine efficacy in patients receiving chronic opioids undergoing spinal surgery

Rev. Soc. Esp. Dolor. 2021; 28(2): 92-99 / DOI: 10.20986/resed.2021.3825/2020

Risk of misuse of prescribed opioids in patients with chronic noncancer pain in a workers compensation system hospital in Chile

Rev. Soc. Esp. Dolor. 2021; 28(2): 82-91 / DOI: 10.20986/resed.2021.3845/2020

Evolution of low back pain in cancer patients treated with interventional pain management

Rev. Soc. Esp. Dolor. 2021; 28(2): 76-81 / DOI: 10.20986/resed.2021.3901/2021

Analgesic effectiveness of tapentadol in neuropathic pain secondary to post-laminectomy syndrome

Rev. Soc. Esp. Dolor. 2021; 28(2): 71-75 / DOI: 10.20986/resed.2021.3822/2020

Radiofrequency intraosseous ablation of the vertebral basicervical nerve. Solution in refractory discogenic pain?

Rev. Soc. Esp. Dolor. 2021; 28(2): 69-70 / DOI: 10.20986/resed.2021.3926/2021

Usefulness or necessity of ketamine in postoperative pain

Rev. Soc. Esp. Dolor. 2021; 28(2): 63-66 / DOI: 10.20986/resed.2021.3921/2021

Parsonage-turner after rabies vaccination due to bat bite: case report

Rev. Soc. Esp. Dolor. 2021; 28(1): 57-61 / DOI: 10.20986/resed.2021.3832/2020

Bilateral spinal erector plane block for pectus excavatum surgery in pediatric patient

Rev. Soc. Esp. Dolor. 2021; 28(1): 53-56 / DOI: 10.20986/resed.2021.3846/2020

Inflammatory mediators: its connection with chronic pain and associated problems. Review

Rev. Soc. Esp. Dolor. 2021; 28(1): 37-46 / DOI: 10.20986/resed.2021.3841/2020

Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

Rev. Soc. Esp. Dolor. 2021; 28(1): 19-26 / DOI: 10.20986/resed.2021.3824/2020

Implementation and evaluation of a multimodal analgesia protocol for total knee arthroplasty including ultrasoundguided adductor canal block and periarticular local anesthetic infiltration

Rev. Soc. Esp. Dolor. 2021; 28(1): 9-18 / DOI: 10.20986/resed.2021.3847/2020

Pain related to oncologic process: old concepts and new horizons

Rev. Soc. Esp. Dolor. 2021; 28(1): 1-4 / DOI: 10.20986/resed.2021.3905/2021

Interventional management of osteoarthritic pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 85-90 / DOI: 10.20986/resed.2021.3853/2020

Intra-articular botulinum toxin and ozone in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 73-79 / DOI: 10.20986/resed.2021.3857/2020

Infiltrations of steroids and hyaluronic acid in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 64-72 / DOI: 10.20986/resed.2021.3854/2020

New pharmacological targets for osteoarthritis induced pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 57-63 / DOI: 10.20986/resed.2021.3863/2020

Opioids in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 49-56 / DOI: 10.20986/resed.2021.3855/2020

Review of the pharmacological treatment of osteoarthritis pain with paracetamol, non-steroid anti-inflammatory (NSAIDSS) and selective cyclooxygenase-2 inhibitors (COXIB)

Rev. Soc. Esp. Dolor. 2021; 28(13): 43-48 / DOI: 10.20986/resed.2021.3864/2020

Central sensitization in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 31-37 / DOI: 10.20986/resed.2021.3876/2020

Experimental models for pain evaluation in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 18-30 / DOI: 10.20986/resed.2021.3872/2020

Ethiopathogenic mechanism of osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 11-17 / DOI: 10.20986/resed.2021.3851/2020

Epidemiology, clinical impact and therapeutic objectives in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 4-10 / DOI: 10.20986/resed.2021.3874/2020

Osteoarthritis and pain: the complexity and impact of a symptom

Rev. Soc. Esp. Dolor. 2021; 28(13): 1-3 / DOI: 10.20986/resed.2021.3886/2021

Adaptation of the chronic pain unit of the Hospital Complex from Vigo to the state of alarm due to the SARS-CoV-2 pandemic

Rev. Soc. Esp. Dolor. 2020; 27(6): 392-393 / DOI: 10.20986/resed.2020.3827/2020

Effectiveness and current recommendation of manual therapy on hip osteoarthritis. An overview

Rev. Soc. Esp. Dolor. 2020; 27(6): 375-391 / DOI: 10.20986/resed.2021.3835/2020

Transitional pain clinic

Rev. Soc. Esp. Dolor. 2020; 27(6): 369-374 / DOI: 10.20986/resed.2020.3840/2020

Study of pain in rehabilitation treatments

Rev. Soc. Esp. Dolor. 2020; 27(6): 361-368 / DOI: 10.20986/resed.2020.3809/2020

Impact of group psychological intervention on conventional radiofrequency tributary patients

Rev. Soc. Esp. Dolor. 2020; 27(6): 349-360 / DOI: 10.20986/resed.2020.3830/2020

Calcific tendinitis of the shoulder: risk factors and effectiveness of iontophoresis with acetic acid 5 % plus ultrasound: prospective quasi-experimental study at 5 years with 138 cases

Rev. Soc. Esp. Dolor. 2020; 27(6): 340-348 / DOI: 10.20986/resed.2020.3842/2020

Physical medicine, rehabilitation and pain

Rev. Soc. Esp. Dolor. 2020; 27(6): 333-335 / DOI: 10.20986/resed.2021.3888/2021

A 14-month physiotherapy follow up to a child with Sandifer syndrome

Rev. Soc. Esp. Dolor. 2020; 27(5): 329-331 / DOI: 10.20986/resed.2020.3816/2020

School of non-oncologic chronic pain patients and opioid treatment

Rev. Soc. Esp. Dolor. 2020; 27(5): 324-328 / DOI: 10.20986/resed.2020.3804/2020

Opioid misuse in patients with cancer pain: an integrative systematic review of the literature

Rev. Soc. Esp. Dolor. 2020; 27(5): 306-315 / DOI: 10.20986/resed.2020.3801/2020

Therapeutic failure of the lumbar medial branch block and its relation to obesity. Retrospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 298-305 / DOI: 10.20986/resed.2020.3829/2020

Identification of signs and symptoms for the diagnosis of discogenic low back pain: mapping review

Rev. Soc. Esp. Dolor. 2020; 27(5): 292-297 / DOI: 10.20986/resed.2020.3803/2020

Efficacy of lidocaine perfusions in fibromyalgia: a prospective cohort study

Rev. Soc. Esp. Dolor. 2020; 27(5): 287-291 / DOI: 10.20986/resed.2020.3796/2020

Back to the future in the treatment of postoperative acute pain

Rev. Soc. Esp. Dolor. 2020; 27(5): 285-286 / DOI: 10.20986/resed.2020.3850/2020

Temporary peripheral nerve stimulation in cancer pain: opportunity options

Rev. Soc. Esp. Dolor. 2020; 27(5): 283-284 / DOI: 10.20986/resed.2020.3849/2020

Facings with discogenic pain

Rev. Soc. Esp. Dolor. 2020; 27(5): 281-282 / DOI: 10.20986/resed.2020.3848/2020

Pain: a "hotchpotch"

Rev. Soc. Esp. Dolor. 2020; 27(4): 278-280 / DOI: 10.20986/resed.2016.3507/2016

Splanchnic nerve block for the treatment of benign chronic abdominal pain. a case report and literature review

Rev. Soc. Esp. Dolor. 2020; 27(4): 273-277 / DOI: 10.20986/resed.2020.3818/2020

Continuous analgesic control in a patient with multiple rib fractures by placing a catheter in the deep plane of the erector muscle of the spine

Rev. Soc. Esp. Dolor. 2020; 27(4): 269-272 / DOI: 10.20986/resed.2020.3800/2020

Clinical pathophysiology in patients with sickle cell disease: the transition from acute to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 257-268 / DOI: 10.20986/resed.2020.3814/2020

Gender determinants in the approach to chronic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 252-256 / DOI: 10.20986/resed.2020.3802/2020

Incidence of postmastectomy pain syndrome. Retrospective analysis

Rev. Soc. Esp. Dolor. 2020; 27(4): 246-251 / DOI: 10.20986/resed.2020.3797/2020

Sociodemographic and clinical characterization in patients with chronic back pain, Cienfuegos 2019

Rev. Soc. Esp. Dolor. 2020; 27(4): 239-245 / DOI: 10.20986/resed.2020.3798/2020

Spinal cord stimulation. Analysis of the diagnostic indications

Rev. Soc. Esp. Dolor. 2020; 27(4): 234-238 / DOI: 10.20986/resed.2020.3777/2019

Updated version of the IASP definition of pain: one step forward or one step back

Rev. Soc. Esp. Dolor. 2020; 27(4): 232-233 / DOI: 10.20986/resed.2020.3839/2020

Metamizole as an immunomodulator in neuropathic pain

Rev. Soc. Esp. Dolor. 2020; 27(4): 230-231 / DOI: 10.20986/resed.2020.3838/2020

Suboccipital decompression as an alternative in the treatment of pain secundary to occipital neuralgia: a case series

Rev. Soc. Esp. Dolor. 2020; 27(3): 221-226 / DOI: 10.20986/resed.2020.3791/2020

Analgesic effect of the capsaicin 8 % patch through the TRPV-1 receptor in a case of parkinson desease with located neuropathic pain

Rev. Soc. Esp. Dolor. 2020; 27(3): 216-22 / DOI: 10.20986/resed.2020.3786/2019

Spanish Pain Society (SPS). Healthcare recommendations for pain units in the face of progressive normalization of activity during the COVID-19 pandemic

Rev. Soc. Esp. Dolor. 2020; 27(3): 192-215 / DOI: 10.20986/resed.2020.3821/2020

Symptomatic treatment for migraña. Drugs used and related variables. Results of the european survey on work and migraine

Rev. Soc. Esp. Dolor. 2020; 27(3): 178-191 / DOI: 10.20986/resed.2020.3744/2019

Characteristics of patients suffering mild to severe pain treated with orodispersible tablets of paracetamol 325 mg/tramadol HCL 37,5mg (Paxiflas®) in comparison with other oral formulations containing the same combination. PROPAX study

Rev. Soc. Esp. Dolor. 2020; 27(3): 168-177 / DOI: 10.20986/resed.2020.3771/2019

Biomechanical factors related to surgical outcomes on patients treated with lumbar arthrodesis in a high complexity center in Colombia

Rev. Soc. Esp. Dolor. 2020; 27(3): 160-167 / DOI: 10.20986/resed.2020.3759/2019

Drug consumption used for musculoskeletal pain treatment in a cohort of blue-collar workers in Zaragoza (Spain)

Rev. Soc. Esp. Dolor. 2020; 27(3): 150-159 / DOI: 10.20986/resed.2020.3749/2019

The pandemic that surprised us and has altered the care of patients with pain

Rev. Soc. Esp. Dolor. 2020; 27(3): 148-149 / DOI: 10.20986/resed.2020.3820/2020

The Pain Units in the COVID-19 era

Rev. Soc. Esp. Dolor. 2020; 27(3): 143-145 / DOI: 10.20986/resed.2020.3823/2020

Erector spinalis plane block as a neuropathic pain management in post-burned pediatric patient

Rev. Soc. Esp. Dolor. 2020; 27(2): 127-132 / DOI: 10.20986/resed.2020.3776/2019

Management of breakthrough pain associated with the cure of skin ulcers

Rev. Soc. Esp. Dolor. 2020; 27(2): 113-126 / DOI: 10.20986/resed.2020.3755/2019

Efficacy of a preincisional analgesic strategy with ibuprofen, paracetamol and dexamethasone in laparoscopic cholecystectomy. Prospective observational study

Rev. Soc. Esp. Dolor. 2020; 27(2): 104-112 / DOI: 10.20986/resed.2020.3778/2019

E-consults, a new tool for pain management. Results of its implementation in an organizational structure of integrated management (EOXI)

Rev. Soc. Esp. Dolor. 2020; 27(2): 97-103 / DOI: 10.20986/resed.2020.3756/2019

Ethical problems in the management of pain. Qualitative study through open reflection interview

Rev. Soc. Esp. Dolor. 2020; 27(2): 89-96 / DOI: 10.20986/resed.2020.3729/2019

Intra-articular ozone modulates inflammation, ameliorates pain and stiffness, improves function and has anabolic effect on knee osteoarthritis: a prospective quasiexperimental before-and-after study, 115 patients

Rev. Soc. Esp. Dolor. 2020; 27(2): 78-88 / DOI: 10.20986/resed.2020.3775/2019

Altruistic conduct: a behavioral strategy to decrease the perception of pain?

Rev. Soc. Esp. Dolor. 2020; 27(2): 76-77 / DOI: 10.20986/resed.2020.3806/2020

COVID-19 coronavirus and chronic pain: uncertainties

Rev. Soc. Esp. Dolor. 2020; 27(2): 72-73 / DOI: 10.20986/resed.2020.3808/2020

The ozone paradigm in pain treatment

Rev. Soc. Esp. Dolor. 2020; 27(2): 69-71 / DOI: 10.20986/resed.2020.3807/2020

Conventional radiofrequency for genicular nerves in treatment of knee osteoarthritis

Rev. Soc. Esp. Dolor. 2020; 27(1): 59-60 / DOI: 10.20986/resed.2016.3515/2016

Review of the impact of acupuncture treatment on the management of nonspecific low back pain

Rev. Soc. Esp. Dolor. 2020; 27(1): 53-58 / DOI: 10.20986/resed.2020.3762/2019

Effectiveness of the association of lacosamide in trigeminal neuralgia

Rev. Soc. Esp. Dolor. 2020; 27(1): 50-52 / DOI: 10.20986/resed.2019.3738/2019

Effectiveness of patient-controlled analgesia in acute and chronic pain after cardiac surgery: a prospective study

Rev. Soc. Esp. Dolor. 2020; 27(1): 24-36 / DOI: 10.20986/resed.2020.3747/2019

Efficacy of pregabalin, gabapentin and duloxetine in neuropathic pain verified by the p-curve analysis

Rev. Soc. Esp. Dolor. 2020; 27(1): 16-23 / DOI: 10.20986/resed.2020.3727/2019

Quasi-experimental study on effectiveness of music therapy to reduce anxiety before an interventional technique in the pain unit

Rev. Soc. Esp. Dolor. 2020; 27(1): 7-15 / DOI: 10.20986/resed.2020.3767/2019

Spinal stimulation modulated automatically. Evidence of closed stimulation systems: towards the pain pacemaker

Rev. Soc. Esp. Dolor. 2020; 27(1): 5-6 / DOI: 10.20986/resed.2020.3793/2020

News in the treatment of back pain: are the future cell therapies?

Rev. Soc. Esp. Dolor. 2020; 27(1): 3-4 / DOI: 10.20986/resed.2020.3792/2020

Considerations for the use of evidence-based practice in the management of people with pain

Rev. Soc. Esp. Dolor. 2019; 26(6): 374-375 / DOI: 10.20986/resed.2019.3712/2018

Intratecal baclophene for the treatment of pain and spasticity in stiff man syndrome: a case report

Rev. Soc. Esp. Dolor. 2019; 26(6): 368-371 / DOI: 10.20986/resed.2019.3745/2019

Key factors governing spinal cord opioid bioavailability in the management of acute pain

Rev. Soc. Esp. Dolor. 2019; 26(6): 359-367 / DOI: 10.20986/resed.2019.3737/2019

Neurolytic procedures for pancreatic cáncer pain: a systematic review and a proposal for an algorithm treatment

Rev. Soc. Esp. Dolor. 2019; 26(6): 342-358 / DOI: 10.20986/resed.2019.3715/2018

Valuation of the relationship between the rotational restriction of high cervical column and high thoracic column in students with and without cervical pain of the Faculty of Sciences of the Rehabilitation

Rev. Soc. Esp. Dolor. 2019; 26(6): 337-341 / DOI: 10.20986/resed.2019.3698/2018

Correlation study between diagnostic opportunity and pain severity in patients with fibromyalgia who enter the Nononcological Chronic Pain Unit at the San Borja Arriarán Clinical Hospital

Rev. Soc. Esp. Dolor. 2019; 26(6): 331-336 / DOI: 10.20986/resed.2019.3690/2018

Correlation between pain and radiological parameters in patients older than 60 years of age with distal radius fracture

Rev. Soc. Esp. Dolor. 2019; 26(6): 324-330 / DOI: 10.20986/resed.2019.3720/2018

Connexins in chronic pain. A new target?

Rev. Soc. Esp. Dolor. 2019; 26(6): 322-323 / DOI: 10.20986/resed.2019.3785/2019

Celiac axis block in cancer pain: medicine of opportunity

Rev. Soc. Esp. Dolor. 2019; 26(6): 317-319 / DOI: 10.20986/resed.2019.3787/2019

Pyoderma gangrenosum, undocumented complication of a spinal cord stimulation

Rev. Soc. Esp. Dolor. 2019; 26(5): 309-312 / DOI: 10.20986/resed.2019.3725/2019

Applicability of scales/indicators for pain monitoring in critically ill patients incapable of verbalizing: a systematic review of the literature

Rev. Soc. Esp. Dolor. 2019; 26(5): 293-303 / DOI: 10.20986/resed.2019.3726/2019

The medical doctors who perform their care and research work in pain units in the use of the internet: identification, characterization and determinants

Rev. Soc. Esp. Dolor. 2019; 26(5): 284-292 / DOI: 10.20986/resed.2019.3713/2018

Validation of the coping strategies to chronic pain reduced questionnaire in the cienfuegan population with chronic back pain (2017-2018)

Rev. Soc. Esp. Dolor. 2019; 26(5): 276-283 / DOI: 10.20986/resed.2019.3732/2019

New strategies for postoperative pain control in tonsillectomy surgery. Is all that glitters gold?

Rev. Soc. Esp. Dolor. 2019; 26(5): 270-275 / DOI: 10.20986/resed.2019.3742/2019

Epidural betamethasone injection in lumbosacral radicular syndrome: effi cacy evaluation for interlaminar and transforaminal approaches

Rev. Soc. Esp. Dolor. 2019; 26(5): 263-269 / DOI: 10.20986/resed.2019.3700/2018

The use of new technologies in patients with chronic pain. A reality that cannot be denied

Rev. Soc. Esp. Dolor. 2019; 26(5): 259-260 / DOI: 10.20986/resed.2019.3766/2019

Epidural injections: caudal, interlaminar or transforaminal. More than a shot

Rev. Soc. Esp. Dolor. 2019; 26(5): 255-258 / DOI: 10.20986/resed.2019.3764/2019

New ACP guidelines for non-radicular low back pain

Rev. Soc. Esp. Dolor. 2019; 26(4): 254-254 / DOI: 10.20986/resed.2017.3590/2017

Painful diabetic foot ulcer amputation avoided thanks to topical sevoflurane

Rev. Soc. Esp. Dolor. 2019; 26(4): 253-253 / DOI: 10.20986/resed.2018.3683/2018

Open-label, prospective, safety, tolerability and sensory function study after of capsaicin 8 % patch repeat treatment in non-diabetic peripheral neuropathic pain: stride study

Rev. Soc. Esp. Dolor. 2019; 26(4): 251-252 / DOI: 10.20986/resed.2017.3564/2017

NMDA antagonism in the treatment of cluster headache

Rev. Soc. Esp. Dolor. 2019; 26(4): 247-250 / DOI: 10.20986/resed.2019.3710/2018

Orofacial pain in the dental clinic

Rev. Soc. Esp. Dolor. 2019; 26(4): 233-242 / DOI: 10.20986/resed.2019.3724/2019

Role of depressive symptomatology, catastrophism and expectation in the efficacy of interventional treatment in chronic low back pain

Rev. Soc. Esp. Dolor. 2019; 26(4): 227-232 / DOI: 10.20986/resed.2019.3704/2018

Characterization of pain in patients with breast cancer attending the Oncology Unit of the San José Hospital

Rev. Soc. Esp. Dolor. 2019; 26(4): 221-226 / DOI: 10.20986/resed.2019.3692/2018

Comparative analysis of vital signs in acutely hospitalized patients according to the pain intensity

Rev. Soc. Esp. Dolor. 2019; 26(4): 215-220 / DOI: 10.20986/resed.2019.3707/2018

The new international classification of diseases (ICD-11) and chronic pain. Pragmatical implications

Rev. Soc. Esp. Dolor. 2019; 26(4): 209-210 / DOI: 10.20986/resed.2019.3752/2019

Manual therapy, a double-edged weapon in the management of chronic pain

Rev. Soc. Esp. Dolor. 2019; 26(3): 206-207 / DOI: 10.20986/resed.2018.3675/2018

Opioid tapering may improve outcomes for chronic pain patients

Rev. Soc. Esp. Dolor. 2019; 26(3): 204-205 / DOI: 10.20986/resed.2017.3615/2017

Body pain, ethics and empathy: Utopia in the time of the mediate?

Rev. Soc. Esp. Dolor. 2019; 26(3): 203-203 / DOI: 10.20986/resed.2017.3599/2017

Erector spinae plane block for multiple unilateral ribs fractures.

Rev. Soc. Esp. Dolor. 2019; 26(3): 199-202 / DOI: 10.20986/resed.2019.3687/2018

Pain in Parkinson's disease. A look at a little known aspect of this pathology

Rev. Soc. Esp. Dolor. 2019; 26(3): 184-198 / DOI: 10.20986/resed.2019.3733/2019

Information and communication technologies applied among medical professionals who perform pain treatment

Rev. Soc. Esp. Dolor. 2019; 26(3): 175-183 / DOI: 10.20986/resed.2019.3709/2018

Pulsed radiofrequency of the dorsal root ganglion for chronic lumbosacral radicular syndrome refractory to epidural steroid injections

Rev. Soc. Esp. Dolor. 2019; 26(3): 166-174 / DOI: 10.20986/resed.2019.3702/2018

Optimization of postoperative pain management based on a new technological tool. Pain map

Rev. Soc. Esp. Dolor. 2019; 26(3): 154-165 / DOI: 10.20986/resed.2019.3696/2018

Sublingual fentanyl for the treatment of breakthrough cancer pain during allergic reactions to chemotherapy infusion

Rev. Soc. Esp. Dolor. 2019; 26(3): 148-153 / DOI: 10.20986/resed.2018.3689/2018

Recent advances in the use of light in pain research. Implications in physiology and pharmacology

Rev. Soc. Esp. Dolor. 2019; 26(3): 146-147 / DOI: 10.20986/resed.2019.3743/2019

Evidence and foresight of ultrasound-guided blocks for the painful shoulder

Rev. Soc. Esp. Dolor. 2019; 26(3): 144-145 / DOI: 10.20986/resed.2019.3741/2019

Situation of acute postoperative pain in the Spanish National Health System. Icts help to reach a “pain-free” hospital an primary care

Rev. Soc. Esp. Dolor. 2019; 26(3): 139-143 / DOI: 10.20986/resed.2019.3739/2019

Explanations on the article “Recommendations based on evidence for the management of neuropathic pain (review of the literature)”

Rev. Soc. Esp. Dolor. 2019; 26(2): 134-137 / DOI: 10.20986/resed.2019.3723/2019

Main pharmacodynamic differences and receptor affinities between serotonin-norepinephrine reuptake inhibitors: clinical implications in the management of neuropathic pain

Rev. Soc. Esp. Dolor. 2019; 26(2): 131-133 / DOI: 10.20986/resed.2017.3597/2017

Top 10 bioethical issues in pain

Rev. Soc. Esp. Dolor. 2019; 26(2): 130-130 / DOI: 10.20986/resed.2018.3694/2018

Pulsed radiofrequency treatment in the neuropathy of the pudendal nerve: report of a case

Rev. Soc. Esp. Dolor. 2019; 26(2): 128-129 / DOI: 10.20986/resed.2016.3517/2016

Does pregabalin is a safe drug? Heart failure associated with pregabalin

Rev. Soc. Esp. Dolor. 2019; 26(2): 124-125 / DOI: 10.20986/resed.2017.3537/2016

Motor block after caudal epidural infiltration: a case report

Rev. Soc. Esp. Dolor. 2019; 26(2): 120-123 / DOI: 10.20986/resed.2018.3669/2018

Myofascial pain syndrome as a cause of postoperative acute pain in hip surgery

Rev. Soc. Esp. Dolor. 2019; 26(2): 117-119 / DOI: 10.20986/resed.2019.3655/2018

Fast opioid detoxification

Rev. Soc. Esp. Dolor. 2019; 26(2): 95-102 / DOI: 10.20986/resed.2019.3681/2018

Dry needling and changes in muscular activity in subjects with myphastial trigger points: case series

Rev. Soc. Esp. Dolor. 2019; 26(2): 89-94 / DOI: 10.20986/resed.2018.3677/2018

Effectiveness of hand crossing to produce analgesia in patients with chronic pain of the upper limb

Rev. Soc. Esp. Dolor. 2019; 26(2): 81-88 / DOI: 10.20986/resed.2019.3674/2018

Profiles of personality and resilience in chronic pain: utility of the CDRISC-10 to discriminate between resilient and vulnerable types

Rev. Soc. Esp. Dolor. 2019; 26(2): 72-80 / DOI: 10.20986/resed.2018.3670/2018

Epidural steroids in lumbar radicular pain: particulate vs. non-particulate. This is the question

Rev. Soc. Esp. Dolor. 2019; 26(2): 70-71 / DOI: 10.20986/resed.2019.3735/2019

Opioids and addiction in chronic pain: is it a problem?, how to address it?

Rev. Soc. Esp. Dolor. 2019; 26(2): 65-67 / DOI: 10.20986/resed.2019.3736/2019

New indication of capsaicin 8 % patch: painful diabetic peripheral neuropathy

Rev. Soc. Esp. Dolor. 2019; 26(1): 60-61 / DOI: 10.20986/resed.2017.3556/2016

Oxytocin and chronic pain in humans

Rev. Soc. Esp. Dolor. 2019; 26(1): 52-58 / DOI: 10.20986/resed.2018.3664/2018

Influence of psychosocial factors in the experience of musculoskeletal pain: a literatura review

Rev. Soc. Esp. Dolor. 2019; 26(1): 44-51 / DOI: 10.20986/resed.2018.3679/2018

Project adapta: adequacy of treatment in breakthrough cancer pain

Rev. Soc. Esp. Dolor. 2019; 26(1): 31-43 / DOI: 10.20986/resed.2018.3661/2018

Psychosocial factors in chronic cancer pain: a Delphi study

Rev. Soc. Esp. Dolor. 2019; 26(1): 21-30 / DOI: 10.20986/resed.2018.3658/2018

Dexmedetomidine versus endovenous lidocaine in breakthrough pain control and functionality in patients with lumbar stenosis

Rev. Soc. Esp. Dolor. 2019; 26(1): 14-20 / DOI: 10.20986/resed.2018.3656/2018

Effects of multimodal treatment in patients with complex regional pain syndrome type 1 with, at least, 6 months of evolution: a descriptive study

Rev. Soc. Esp. Dolor. 2019; 26(1): 6-13 / DOI: 10.20986/resed.2018.3651/2018

Micro RNAs: A new way for the management of neuropathic pain?

Rev. Soc. Esp. Dolor. 2019; 26(1): 2-3 / DOI: 10.20986/resed.2019.3730/2019

Academic University training program of the Spanish Pain Society

Rev. Soc. Esp. Dolor. 2018; 25(6): 368-368

ACNES as a cause of chronic abdominal pain

Rev. Soc. Esp. Dolor. 2018; 25(6): 360-361 / DOI: 10.20986/resed.2017.3530/2016

Dysphonia as side-effect dose-dependent during treatment with duloxetine

Rev. Soc. Esp. Dolor. 2018; 25(6): 359-359 / DOI: 10.20986/resed.2017.3528/2016

Evidence-based recommendations for the management of neuropathic pain (review of the literature)

Rev. Soc. Esp. Dolor. 2018; 25(6): 349-358 / DOI: 10.20986/resed.2018.3673/2018

Changes in intraocular pressure in patients with trigeminal neuralgia subject to radio frequency of the Gasserian ganglion

Rev. Soc. Esp. Dolor. 2018; 25(6): 342-348 / DOI: 10.20986/resed.2018.3657/2018

Nerve distribution in human temporomandibular articular disc using Sihler staining technique: a cadaveric descriptive approach

Rev. Soc. Esp. Dolor. 2018; 25(6): 335-341 / DOI: 10.20986/resed.2018.3646/2017

Opinaudit study: clinical uses in breakthrough pain, is scientific evidence being followed up?

Rev. Soc. Esp. Dolor. 2018; 25(6): 325-334 / DOI: 10.20986/resed.2018.3634/2017

Use of major opioids for control of pain in hospitalized patients

Rev. Soc. Esp. Dolor. 2018; 25(6): 318-324 / DOI: 10.20986/resed.2018.3629/2017

Proctalgia and pudendal nerve entrapment: an association to know

Rev. Soc. Esp. Dolor. 2018; 25(6): 311-317 / DOI: 10.20986/resed.2018.3623/2017

Consensus for the definition of post-mastectomy pain syndrome

Rev. Soc. Esp. Dolor. 2018; 25(5): 305-306 / DOI: 10.20986/resed.2016.3510/2016

Radiofrequency thermal and splanchnics nerves block

Rev. Soc. Esp. Dolor. 2018; 25(5): 303-304 / DOI: 10.20986/resed.2016.3509/2016

Implications of bioethics in the treatment of chronic pain: the change of paradigms

Rev. Soc. Esp. Dolor. 2018; 25(5): 291-300 / DOI: 10.20986/resed.2018.3666/2018

Farmacologic adyuvants with saving effect of opioids in the perioperative period

Rev. Soc. Esp. Dolor. 2018; 25(5): 278-290 / DOI: 10.20986/resed.2018.3663/2018

Experience in two hospitals about the observation of pain responses in hospitalized preterm infants

Rev. Soc. Esp. Dolor. 2018; 25(5): 271-277 / DOI: 10.20986/resed.2018.3633/2017

Platelet-rich plasma in treating peripheral neuropathic pain. Preliminary report

Rev. Soc. Esp. Dolor. 2018; 25(5): 263-270 / DOI: 10.20986/resed.2017.3625/2017

Pain in the elderly and in patients with cognitive deficit. A DELPHI study

Rev. Soc. Esp. Dolor. 2018; 25(5): 251-262 / DOI: 10.20986/resed.2017.3621/2017

Chrono study: prevalence of breakthrough pain among patients with non-cancer chronic pain in Andalusia, Spain

Rev Soc Esp Dolor 2018; 25(4): 214-221 / DOI: 10.20986/resed.2017.3626/2017

Trial therapy on laterality and motor imagery and selective glenohumeral muscle activation in patients with massive rotator cuff tear: case series

Rev Soc Esp Dolor 2018; 25(4): 197-206 / DOI: 10.20986/resed.2017.3610/2017

Expenditure, prescription and consumption of analgesic drugs before and during the economic crisis

Rev Soc Esp Dolor 2018; 25(3): 155-162 / DOI: 10.20986/resed.2017.3609/2017

Sex and pain: sexual satisfaction and sexual function in a sample of patients with chronic, non-pelvic pain

Rev Soc Esp Dolor 2018; 25(3): 145-154 / DOI: 10.20986/resed.2018.3600/2017

Bibliometric analysis of the Journal of the Spanish Pain Society: 2007-2016

Rev Soc Esp Dolor 2018; 25(3):170-177 / DOI: 10.20986/resed.2018.3627/2017

Painometer v2®: a mobile application certified for monitoring patients with pain

Rev Soc Esp Dolor 2018; 25(2):112-120 / DOI: 10.20986/resed.2017.3555/2016

Analgesic efficacy of topical sevoflurane on wounds

Rev Soc Esp Dolor 2018; 25(2): 106-111 / DOI: 10.20986/resed.2017.3617/2017

Pharmacological management of acute postoperative pain in Spain. Data from the national survey by the Spanish Pain Society (SED)

Rev Soc Esp Dolor 2018; 25(2): 70-85 / DOI: 10.20986/resed.2017.3593/2017

Potential uses of Mirtazapine in palliative care beyond its antidepressant effect

Rev Soc Esp Dolor 2018; 25(1): 37-44 / DOI: 10.20986/resed.2017.3575/2017

Prevalence of pain in patients hospitalized in Metabolic Intensive Care Units with orotracheal intubation and under sedation, measured with the COMFORT scale

Rev Soc Esp Dolor 2018; 25(1): 7-12 / DOI: 10.20986/resed.2017.3581/2017

Pain management in cancer patients receiving radiotherapy: GORVAMUR study, a prospective, observational, epidemiological study

Rev Soc Esp Dolor 2017; 24(5): 241-255 / DOI: 10.20986/resed.2017.3570/2017

Epidural analgesia vs. surgical wound analgesia to control acute post-operative pain in open colon surgery

Rev Soc Esp Dolor 2017; 24(5): 234-240 / DOI: 10.20986/resed.2017.3559/2016

CAD-R. Chronic pain coping questionnaire: confirmatory factor analysis. Are there individual differences in gender, age and type of pain?

Rev Soc Esp Dolor 2017; 24(5): 224-233 / DOI: 10.20986/resed.2017.3558/2016

Intervention of manual motor skill exercises on pain and functionality in adults subjects with rheumatoid arthritis: case series

Rev Soc Esp Dolor 2017; 24(6): 294-303 / DOI: 10.20986/resed.2017.3576/2017

Characterization of chest pain in patients attending the emergency department of a high-complexity-level healthcare institution, during 2014-2015, in Medellín, Colombia

Rev Soc Esp Dolor 2017; 24(6): 288-293 / DOI: 10.20986/resed.2017.3571/2017

Chronic pain: relationship with prefrontal symptoms and perceived stress

Rev Soc Esp Dolor 2017; 24(4): 179-187 / DOI: 10.20986/resed.2017.3540/2016

The effectiveness of electrical spinal-cord stimulation in type i complex regional pain syndrome. A literature review

Rev Soc Esp Dolor 2017; 24(4): 169-178 / DOI: 10.20986/resed.2016.3501/2016

Paxiflas®: new FDT combination of tramadol/paracetamol for treating moderate to severe pain

Rev Soc Esp Dolor 2017; 24(2):59-67 / DOI: 10.20986/resed.2017.3565/2017

The predictive role of rumination and trait mindfulness in pain and negative mood after a sport injury: a longitudinal study

Rev Soc Esp Dolor 2017; 24(3):125-131 / DOI: 10.20986/resed.2017.3495/2016

Prevalence of breakthrough pain associated with chronic low back pain in Andalusia (COLUMBUS study)

Rev Soc Esp Dolor 2017; 24(3):116-124 / DOI: 10.20986/resed.2017.3548/2016

Effectiveness of hyaluronic acid intra-articular injections in treating knee osteoarthritis: results of a series of cases treated in a Pain Unit

Rev Soc Esp Dolor 2017; 24(2): 74-84 / DOI: 10.20986/resed.2016.3485/2016

Prescribing strong opioids in patients with non-cancer pain: a description of their characteristics in an area of primary healthcare assistance

Rev Soc Esp Dolor 2017; 24(1): 19-26 / DOI: 10.20986/resed.2016.3471/2016

Factors associated with pain intensity in Mexican patients hospitalized in postoperative period

Rev Soc Esp Dolor 2017; 24(1): 4-10 / DOI: 10.20986/resed.2016.3442/2016

Instrucciones para citar

Libran Oriol A, Cruz-Sequeiros C, Luque-Blanco A, Porta-Sales J. Peripheral acting Mu opioid receptor antagonists in the treatment of the opioid-induced constipation: review. Rev Soc Esp Dolor 2020; 27(1): 37-49 / DOI: 1020986/resed20203717/2018


Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 65087 veces.
Este artículo ha sido descargado 73 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 11/12/2018

Aceptado: 13/01/2020

Prepublicado: 15/01/2020

Publicado: 19/02/2020

Tiempo de revisión del artículo: 356 días

Tiempo de prepublicación: 400 días

Tiempo de edición del artículo: 435 días


Compartir

Este artículo aun no tiene valoraciones.
Reader rating:
Rate this article:
Send by e-mail
© 2024 Revista de la Sociedad Española del Dolor
ISSN: 1134-8046   e-ISSN: 2254-6189

       Indexada en:
Política de Privacidad